Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

For appropriate patients with type 2 diabetes…
Start with the goal-getting power of Janumet.
2 million prescriptions. Over 2 years of proven experience.

The power to get more patients to ADA goal (A1C < 7.0%) vs merformin alone.

For more information, please visit janumet.com/hcp

For appropriate patients with type 2 diabetes…
Janumet: Powerful and sustained A1C reductions over 2 years.

When you have decided not to use merformin…
Januvia: lower A1C levels sustained over 2 years – similar to metformin monotherapy.
10 million prescriptions. Over 2 years of proven experience.

Brand name: Janumet and Januvia
Generic name/category: Sitagliptin and Metformin
Company: Merck
Country/Market: USA, North America
Indication(s)/use: diabetes, hyperglycemia
Target: Healthcare Professionals (HCP)
Publication: Formulary June 2009

To see all of the ads from this campaign, click here
To see all of this brand’s ads on AdPharm, click here

Today, I took steps to balance my type 2 diabetes.
Today, I chose salad and talked to my doctor.

It’s time. Crestor

Call 1-888-JANUVIA or visit Januvia.com

A different way. Januvia.

Sitagliptin (INN; previously identified as MK-0431, trade name Januvia) is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, Sitagliptin being the only 2nd Generation DPP4 inhibitor currently available. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. Exenatide (Byetta) is an alternative drug that also works with the incretin system. – Wikipedia

US News and World Report February 2009